Topical Anti‐Inflammatory Treatments for Eczema: A Cochrane Systematic Review and Network Meta‐Analysis

ABSTRACT Objective Eczema is the most burdensome skin condition worldwide and topical anti‐inflammatory treatments are commonly used to control symptoms. The relative effectiveness and safety of different topical anti‐inflammatory treatments is uncertain. Design Network meta‐analysis performed withi...

Full description

Saved in:
Bibliographic Details
Published inClinical and experimental allergy Vol. 54; no. 12; pp. 960 - 972
Main Authors Lax, Stephanie J., Van Vogt, Eleanor, Candy, Bridget, Steele, Lloyd, Reynolds, Clare, Stuart, Beth, Parker, Roses, Axon, Emma, Roberts, Amanda, Doyle, Megan, Chu, Derek K., Futamura, Masaki, Santer, Miriam, Williams, Hywel C., Cro, Suzie, Drucker, Aaron M., Boyle, Robert J.
Format Journal Article
LanguageEnglish
Published England Wiley Subscription Services, Inc 01.12.2024
John Wiley and Sons Inc
Subjects
Online AccessGet full text
ISSN0954-7894
1365-2222
1365-2222
DOI10.1111/cea.14556

Cover

Loading…
Abstract ABSTRACT Objective Eczema is the most burdensome skin condition worldwide and topical anti‐inflammatory treatments are commonly used to control symptoms. The relative effectiveness and safety of different topical anti‐inflammatory treatments is uncertain. Design Network meta‐analysis performed within a Cochrane systematic review to compare and statistically rank efficacy and safety of topical anti‐inflammatory eczema treatments. Data Sources Cochrane Skin Specialised Register, CENTRAL, MEDLINE, Embase and trial registries to June 2023. Eligibility Criteria for Selected Trials Included trials were within‐participant or between‐participant randomised controlled trials. Participants had eczema that was not clinically infected and was not contact dermatitis, seborrheic eczema or hand eczema. Interventions were topical anti‐inflammatory treatments but not complementary treatments, antibiotics alone, wet wraps, phototherapy or systemic treatments. Comparators were no treatment/vehicle or another topical anti‐inflammatory. Results We identified 291 trials (45,846 participants), mainly in high‐income countries. Most were industry‐funded with median 3 weeks treatment duration. Risk of bias assessed using the Cochrane Risk of Bias 2.0 tool was high in 89% of trials, mainly due to risk of selective reporting. Network meta‐analysis of binary outcomes ranked potent and/or very potent topical steroids, tacrolimus 0.1% and ruxolitinib 1.5% among the most effective treatments for improving patient‐reported symptoms (40 trials, all low confidence) and clinician‐reported signs (32 trials, all moderate confidence). For investigator global assessment, the Janus kinas inhibitors ruxolitinib 1.5%, delgocitinib 0.5% or 0.25%, very potent/potent topical steroids and tacrolimus 0.1% were ranked as most effective (140 trials, all moderate confidence). Continuous outcome data were mixed. Local application site reactions were most common with tacrolimus 0.1% (moderate confidence) and crisaborole 2% (high confidence) and least common with topical steroids (moderate confidence). Skin thinning was not increased with short‐term use of any topical steroid potency (low confidence) but skin thinning was reported in 6/2044 (0.3%) participants treated with longer‐term (6–60 months) topical steroids. Conclusion Potent topical steroids, Janus kinase inhibitors and tacrolimus 0.1% were consistently ranked as among the most effective topical anti‐inflammatory treatments for eczema. Trials of topical anti‐inflammatory eczema treatments are mostly industry‐funded, evaluate short‐term outcomes and carry a high risk of bias due to selective reporting. Data from almost 300 trials suggest that potent steroids, Janus kinase inhibitors and tacrolimus 0.1% are among the most effective topical treatments. Local reactions were most common with tacrolimus 0.1% and crisaborole and least common with steroids.
AbstractList Eczema is the most burdensome skin condition worldwide and topical anti-inflammatory treatments are commonly used to control symptoms. The relative effectiveness and safety of different topical anti-inflammatory treatments is uncertain.OBJECTIVEEczema is the most burdensome skin condition worldwide and topical anti-inflammatory treatments are commonly used to control symptoms. The relative effectiveness and safety of different topical anti-inflammatory treatments is uncertain.Network meta-analysis performed within a Cochrane systematic review to compare and statistically rank efficacy and safety of topical anti-inflammatory eczema treatments.DESIGNNetwork meta-analysis performed within a Cochrane systematic review to compare and statistically rank efficacy and safety of topical anti-inflammatory eczema treatments.Cochrane Skin Specialised Register, CENTRAL, MEDLINE, Embase and trial registries to June 2023.DATA SOURCESCochrane Skin Specialised Register, CENTRAL, MEDLINE, Embase and trial registries to June 2023.Included trials were within-participant or between-participant randomised controlled trials. Participants had eczema that was not clinically infected and was not contact dermatitis, seborrheic eczema or hand eczema. Interventions were topical anti-inflammatory treatments but not complementary treatments, antibiotics alone, wet wraps, phototherapy or systemic treatments. Comparators were no treatment/vehicle or another topical anti-inflammatory.ELIGIBILITY CRITERIA FOR SELECTED TRIALSIncluded trials were within-participant or between-participant randomised controlled trials. Participants had eczema that was not clinically infected and was not contact dermatitis, seborrheic eczema or hand eczema. Interventions were topical anti-inflammatory treatments but not complementary treatments, antibiotics alone, wet wraps, phototherapy or systemic treatments. Comparators were no treatment/vehicle or another topical anti-inflammatory.We identified 291 trials (45,846 participants), mainly in high-income countries. Most were industry-funded with median 3 weeks treatment duration. Risk of bias assessed using the Cochrane Risk of Bias 2.0 tool was high in 89% of trials, mainly due to risk of selective reporting. Network meta-analysis of binary outcomes ranked potent and/or very potent topical steroids, tacrolimus 0.1% and ruxolitinib 1.5% among the most effective treatments for improving patient-reported symptoms (40 trials, all low confidence) and clinician-reported signs (32 trials, all moderate confidence). For investigator global assessment, the Janus kinas inhibitors ruxolitinib 1.5%, delgocitinib 0.5% or 0.25%, very potent/potent topical steroids and tacrolimus 0.1% were ranked as most effective (140 trials, all moderate confidence). Continuous outcome data were mixed. Local application site reactions were most common with tacrolimus 0.1% (moderate confidence) and crisaborole 2% (high confidence) and least common with topical steroids (moderate confidence). Skin thinning was not increased with short-term use of any topical steroid potency (low confidence) but skin thinning was reported in 6/2044 (0.3%) participants treated with longer-term (6-60 months) topical steroids.RESULTSWe identified 291 trials (45,846 participants), mainly in high-income countries. Most were industry-funded with median 3 weeks treatment duration. Risk of bias assessed using the Cochrane Risk of Bias 2.0 tool was high in 89% of trials, mainly due to risk of selective reporting. Network meta-analysis of binary outcomes ranked potent and/or very potent topical steroids, tacrolimus 0.1% and ruxolitinib 1.5% among the most effective treatments for improving patient-reported symptoms (40 trials, all low confidence) and clinician-reported signs (32 trials, all moderate confidence). For investigator global assessment, the Janus kinas inhibitors ruxolitinib 1.5%, delgocitinib 0.5% or 0.25%, very potent/potent topical steroids and tacrolimus 0.1% were ranked as most effective (140 trials, all moderate confidence). Continuous outcome data were mixed. Local application site reactions were most common with tacrolimus 0.1% (moderate confidence) and crisaborole 2% (high confidence) and least common with topical steroids (moderate confidence). Skin thinning was not increased with short-term use of any topical steroid potency (low confidence) but skin thinning was reported in 6/2044 (0.3%) participants treated with longer-term (6-60 months) topical steroids.Potent topical steroids, Janus kinase inhibitors and tacrolimus 0.1% were consistently ranked as among the most effective topical anti-inflammatory treatments for eczema.CONCLUSIONPotent topical steroids, Janus kinase inhibitors and tacrolimus 0.1% were consistently ranked as among the most effective topical anti-inflammatory treatments for eczema.
Trials of topical anti‐inflammatory eczema treatments are mostly industry‐funded, evaluate short‐term outcomes and carry a high risk of bias due to selective reporting. Data from almost 300 trials suggest that potent steroids, Janus kinase inhibitors and tacrolimus 0.1% are among the most effective topical treatments. Local reactions were most common with tacrolimus 0.1% and crisaborole and least common with steroids.
Eczema is the most burdensome skin condition worldwide and topical anti-inflammatory treatments are commonly used to control symptoms. The relative effectiveness and safety of different topical anti-inflammatory treatments is uncertain. Network meta-analysis performed within a Cochrane systematic review to compare and statistically rank efficacy and safety of topical anti-inflammatory eczema treatments. Cochrane Skin Specialised Register, CENTRAL, MEDLINE, Embase and trial registries to June 2023. Included trials were within-participant or between-participant randomised controlled trials. Participants had eczema that was not clinically infected and was not contact dermatitis, seborrheic eczema or hand eczema. Interventions were topical anti-inflammatory treatments but not complementary treatments, antibiotics alone, wet wraps, phototherapy or systemic treatments. Comparators were no treatment/vehicle or another topical anti-inflammatory. We identified 291 trials (45,846 participants), mainly in high-income countries. Most were industry-funded with median 3 weeks treatment duration. Risk of bias assessed using the Cochrane Risk of Bias 2.0 tool was high in 89% of trials, mainly due to risk of selective reporting. Network meta-analysis of binary outcomes ranked potent and/or very potent topical steroids, tacrolimus 0.1% and ruxolitinib 1.5% among the most effective treatments for improving patient-reported symptoms (40 trials, all low confidence) and clinician-reported signs (32 trials, all moderate confidence). For investigator global assessment, the Janus kinas inhibitors ruxolitinib 1.5%, delgocitinib 0.5% or 0.25%, very potent/potent topical steroids and tacrolimus 0.1% were ranked as most effective (140 trials, all moderate confidence). Continuous outcome data were mixed. Local application site reactions were most common with tacrolimus 0.1% (moderate confidence) and crisaborole 2% (high confidence) and least common with topical steroids (moderate confidence). Skin thinning was not increased with short-term use of any topical steroid potency (low confidence) but skin thinning was reported in 6/2044 (0.3%) participants treated with longer-term (6-60 months) topical steroids. Potent topical steroids, Janus kinase inhibitors and tacrolimus 0.1% were consistently ranked as among the most effective topical anti-inflammatory treatments for eczema.
ABSTRACT Objective Eczema is the most burdensome skin condition worldwide and topical anti‐inflammatory treatments are commonly used to control symptoms. The relative effectiveness and safety of different topical anti‐inflammatory treatments is uncertain. Design Network meta‐analysis performed within a Cochrane systematic review to compare and statistically rank efficacy and safety of topical anti‐inflammatory eczema treatments. Data Sources Cochrane Skin Specialised Register, CENTRAL, MEDLINE, Embase and trial registries to June 2023. Eligibility Criteria for Selected Trials Included trials were within‐participant or between‐participant randomised controlled trials. Participants had eczema that was not clinically infected and was not contact dermatitis, seborrheic eczema or hand eczema. Interventions were topical anti‐inflammatory treatments but not complementary treatments, antibiotics alone, wet wraps, phototherapy or systemic treatments. Comparators were no treatment/vehicle or another topical anti‐inflammatory. Results We identified 291 trials (45,846 participants), mainly in high‐income countries. Most were industry‐funded with median 3 weeks treatment duration. Risk of bias assessed using the Cochrane Risk of Bias 2.0 tool was high in 89% of trials, mainly due to risk of selective reporting. Network meta‐analysis of binary outcomes ranked potent and/or very potent topical steroids, tacrolimus 0.1% and ruxolitinib 1.5% among the most effective treatments for improving patient‐reported symptoms (40 trials, all low confidence) and clinician‐reported signs (32 trials, all moderate confidence). For investigator global assessment, the Janus kinas inhibitors ruxolitinib 1.5%, delgocitinib 0.5% or 0.25%, very potent/potent topical steroids and tacrolimus 0.1% were ranked as most effective (140 trials, all moderate confidence). Continuous outcome data were mixed. Local application site reactions were most common with tacrolimus 0.1% (moderate confidence) and crisaborole 2% (high confidence) and least common with topical steroids (moderate confidence). Skin thinning was not increased with short‐term use of any topical steroid potency (low confidence) but skin thinning was reported in 6/2044 (0.3%) participants treated with longer‐term (6–60 months) topical steroids. Conclusion Potent topical steroids, Janus kinase inhibitors and tacrolimus 0.1% were consistently ranked as among the most effective topical anti‐inflammatory treatments for eczema. Trials of topical anti‐inflammatory eczema treatments are mostly industry‐funded, evaluate short‐term outcomes and carry a high risk of bias due to selective reporting. Data from almost 300 trials suggest that potent steroids, Janus kinase inhibitors and tacrolimus 0.1% are among the most effective topical treatments. Local reactions were most common with tacrolimus 0.1% and crisaborole and least common with steroids.
ObjectiveEczema is the most burdensome skin condition worldwide and topical anti‐inflammatory treatments are commonly used to control symptoms. The relative effectiveness and safety of different topical anti‐inflammatory treatments is uncertain.DesignNetwork meta‐analysis performed within a Cochrane systematic review to compare and statistically rank efficacy and safety of topical anti‐inflammatory eczema treatments.Data SourcesCochrane Skin Specialised Register, CENTRAL, MEDLINE, Embase and trial registries to June 2023.Eligibility Criteria for Selected TrialsIncluded trials were within‐participant or between‐participant randomised controlled trials. Participants had eczema that was not clinically infected and was not contact dermatitis, seborrheic eczema or hand eczema. Interventions were topical anti‐inflammatory treatments but not complementary treatments, antibiotics alone, wet wraps, phototherapy or systemic treatments. Comparators were no treatment/vehicle or another topical anti‐inflammatory.ResultsWe identified 291 trials (45,846 participants), mainly in high‐income countries. Most were industry‐funded with median 3 weeks treatment duration. Risk of bias assessed using the Cochrane Risk of Bias 2.0 tool was high in 89% of trials, mainly due to risk of selective reporting. Network meta‐analysis of binary outcomes ranked potent and/or very potent topical steroids, tacrolimus 0.1% and ruxolitinib 1.5% among the most effective treatments for improving patient‐reported symptoms (40 trials, all low confidence) and clinician‐reported signs (32 trials, all moderate confidence). For investigator global assessment, the Janus kinas inhibitors ruxolitinib 1.5%, delgocitinib 0.5% or 0.25%, very potent/potent topical steroids and tacrolimus 0.1% were ranked as most effective (140 trials, all moderate confidence). Continuous outcome data were mixed. Local application site reactions were most common with tacrolimus 0.1% (moderate confidence) and crisaborole 2% (high confidence) and least common with topical steroids (moderate confidence). Skin thinning was not increased with short‐term use of any topical steroid potency (low confidence) but skin thinning was reported in 6/2044 (0.3%) participants treated with longer‐term (6–60 months) topical steroids.ConclusionPotent topical steroids, Janus kinase inhibitors and tacrolimus 0.1% were consistently ranked as among the most effective topical anti‐inflammatory treatments for eczema.
Author Reynolds, Clare
Futamura, Masaki
Santer, Miriam
Axon, Emma
Lax, Stephanie J.
Candy, Bridget
Chu, Derek K.
Cro, Suzie
Parker, Roses
Stuart, Beth
Roberts, Amanda
Boyle, Robert J.
Van Vogt, Eleanor
Steele, Lloyd
Doyle, Megan
Williams, Hywel C.
Drucker, Aaron M.
AuthorAffiliation 4 Wellcome Sanger Institute Cambridge UK
5 School of Public Health, Physiotherapy and Sports Science, University College Dublin Dublin Ireland
3 Department of Dermatology Royal Free Hospital London UK
6 Primary Care and Population Sciences, Faculty of Medicine University of Southampton Southampton UK
7 Cochrane MOSS Network, c/o Cochrane Pain Palliative and Supportive Care Group Oxford UK
8 Cochrane Methods Support Unit Cochrane London UK
9 Nottingham Support Group for Carers of Children With Eczema Nottingham UK
14 Department of Medicine, Research and Innovation Institute Women's College Hospital Toronto Ontario Canada
11 Department of Health Research Methods, Evidence & Impact McMaster University Hamilton Ontario Canada
13 Department of Medicine University of Toronto Toronto Ontario Canada
12 Department of Pediatrics National Hospital Organization Nagoya Medical Center Nagoya Japan
2 Imperial Clinical Trials Unit Imperial College London London UK
1 Centre of Evidence Based Dermatology University
AuthorAffiliation_xml – name: 3 Department of Dermatology Royal Free Hospital London UK
– name: 15 Section of Inflammation and Repair, National Heart & Lung Institute Imperial College London London UK
– name: 9 Nottingham Support Group for Carers of Children With Eczema Nottingham UK
– name: 8 Cochrane Methods Support Unit Cochrane London UK
– name: 1 Centre of Evidence Based Dermatology University of Nottingham Nottingham UK
– name: 13 Department of Medicine University of Toronto Toronto Ontario Canada
– name: 5 School of Public Health, Physiotherapy and Sports Science, University College Dublin Dublin Ireland
– name: 11 Department of Health Research Methods, Evidence & Impact McMaster University Hamilton Ontario Canada
– name: 4 Wellcome Sanger Institute Cambridge UK
– name: 12 Department of Pediatrics National Hospital Organization Nagoya Medical Center Nagoya Japan
– name: 7 Cochrane MOSS Network, c/o Cochrane Pain Palliative and Supportive Care Group Oxford UK
– name: 6 Primary Care and Population Sciences, Faculty of Medicine University of Southampton Southampton UK
– name: 14 Department of Medicine, Research and Innovation Institute Women's College Hospital Toronto Ontario Canada
– name: 2 Imperial Clinical Trials Unit Imperial College London London UK
– name: 10 Department of Medicine McMaster University Hamilton Ontario Canada
Author_xml – sequence: 1
  givenname: Stephanie J.
  orcidid: 0000-0002-7000-9364
  surname: Lax
  fullname: Lax, Stephanie J.
  organization: University of Nottingham
– sequence: 2
  givenname: Eleanor
  surname: Van Vogt
  fullname: Van Vogt, Eleanor
  organization: Imperial College London
– sequence: 3
  givenname: Bridget
  surname: Candy
  fullname: Candy, Bridget
  organization: Royal Free Hospital
– sequence: 4
  givenname: Lloyd
  surname: Steele
  fullname: Steele, Lloyd
  organization: Wellcome Sanger Institute
– sequence: 5
  givenname: Clare
  surname: Reynolds
  fullname: Reynolds, Clare
  organization: School of Public Health, Physiotherapy and Sports Science, University College Dublin
– sequence: 6
  givenname: Beth
  surname: Stuart
  fullname: Stuart, Beth
  organization: University of Southampton
– sequence: 7
  givenname: Roses
  surname: Parker
  fullname: Parker, Roses
  organization: Cochrane MOSS Network, c/o Cochrane Pain Palliative and Supportive Care Group
– sequence: 8
  givenname: Emma
  surname: Axon
  fullname: Axon, Emma
  organization: Cochrane
– sequence: 9
  givenname: Amanda
  surname: Roberts
  fullname: Roberts, Amanda
  organization: Nottingham Support Group for Carers of Children With Eczema
– sequence: 10
  givenname: Megan
  surname: Doyle
  fullname: Doyle, Megan
  organization: University of Nottingham
– sequence: 11
  givenname: Derek K.
  orcidid: 0000-0001-8269-4496
  surname: Chu
  fullname: Chu, Derek K.
  organization: McMaster University
– sequence: 12
  givenname: Masaki
  surname: Futamura
  fullname: Futamura, Masaki
  organization: National Hospital Organization Nagoya Medical Center
– sequence: 13
  givenname: Miriam
  surname: Santer
  fullname: Santer, Miriam
  organization: University of Southampton
– sequence: 14
  givenname: Hywel C.
  surname: Williams
  fullname: Williams, Hywel C.
  organization: University of Nottingham
– sequence: 15
  givenname: Suzie
  orcidid: 0000-0002-6113-1173
  surname: Cro
  fullname: Cro, Suzie
  organization: Imperial College London
– sequence: 16
  givenname: Aaron M.
  surname: Drucker
  fullname: Drucker, Aaron M.
  organization: Women's College Hospital
– sequence: 17
  givenname: Robert J.
  orcidid: 0000-0002-4913-7580
  surname: Boyle
  fullname: Boyle, Robert J.
  email: r.boyle@imperial.ac.uk
  organization: Imperial College London
BackLink https://www.ncbi.nlm.nih.gov/pubmed/39219446$$D View this record in MEDLINE/PubMed
BookMark eNp9kc1uEzEUhS3UiqaFBS-ALLGBxbT22PNjNmgUhVKpgARhbd06d6jbmXGwnUbDqo_QZ-yT4DSlgkpwF7Zkf_foHJ19sjO4AQl5wdkhT3NkEA65LIryCZlwURZZnmaHTJgqZFbVSu6R_RAuGGOiUPVTsidUzpWU5YRczt3SGuhoM0R7e31zMrQd9D1E50c69wixxyEG2jpPZ-Yn9vCWNnTqzLmHAenXMcT0Fq2hX_DK4prCsKCfMK6dv6QfMULSbAboxmDDM7LbQhfw-f19QL69n82nH7LTz8cn0-Y0MzJ5ymQpVLk5ANtFXQusRMUQC9WaltcLkBy4yWUrSpajUK2SmEvgFSgwlThj4oC82-ouV2c9LkwK4KHTS2978KN2YPXfP4M919_dlea8zBUreFJ4fa_g3Y8Vhqh7Gwx2XcrsVkELplRdVFIWCX31CL1wK58SJ4rLXOYshUnUyz8tPXj5XUQC3mwB410IHtsHhDO9KVmnkvVdyYk9esQaG1MHbpPGdv_bWNsOx39L6-ms2W78AsGauhI
CitedBy_id crossref_primary_10_1111_cea_14601
crossref_primary_10_1111_cea_14618
Cites_doi 10.1136/bmj.n71
10.1371/journal.pmed.1003082
10.1002/ski2.268
10.1111/cea.14515
10.1111/bjd.15179
10.1111/bjd.18780
10.7326/M14-2385
10.1371/journal.pone.0076654
10.1038/jid.2013.446
10.1016/j.jaad.2021.06.002
10.1111/cea.13784
10.1136/bmj.l4898
10.1159/000245677
10.1016/j.jid.2016.05.104
10.1016/j.jaci.2003.12.591
10.1111/cea.14085
10.1111/cea.14276
10.1080/09546630410033781
10.1177/1536867X1501500403
10.1016/j.jaci.2023.08.030
10.1111/cea.14263
10.1111/cea.14274
10.1093/ije/dys222
10.1542/peds.2014-1990
10.1111/cea.14301
10.1111/j.1365-2230.1994.tb01167.x
10.1080/03007995.2019.1699516
10.1016/j.jaci.2014.07.043
10.1034/j.1600-0625.2001.100102.x
10.1016/j.jaci.2023.03.008
10.1136/bmj.n2202
10.1111/j.1365-2133.2005.06592.x
ContentType Journal Article
Copyright 2024 The Author(s). published by John Wiley & Sons Ltd.
2024 The Author(s). Clinical & Experimental Allergy published by John Wiley & Sons Ltd.
2024. This article is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml – notice: 2024 The Author(s). published by John Wiley & Sons Ltd.
– notice: 2024 The Author(s). Clinical & Experimental Allergy published by John Wiley & Sons Ltd.
– notice: 2024. This article is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID 24P
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7T5
H94
K9.
7X8
5PM
DOI 10.1111/cea.14556
DatabaseName Wiley Online Library Open Access (Activated by CARLI)
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Immunology Abstracts
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Immunology Abstracts
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic

MEDLINE

AIDS and Cancer Research Abstracts
Database_xml – sequence: 1
  dbid: 24P
  name: Wiley Online Library Open Access
  url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html
  sourceTypes: Publisher
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Biology
EISSN 1365-2222
EndPage 972
ExternalDocumentID PMC11629051
39219446
10_1111_cea_14556
CEA14556
Genre reviewArticle
Systematic Review
Journal Article
Network Meta-Analysis
GrantInformation_xml – fundername: National Institute for Health and Care Research
  funderid: NIHR201993
– fundername: National Institute for Health and Care Research
  grantid: NIHR201993
GroupedDBID ---
.3N
.55
.GA
.Y3
05W
0R~
10A
1OB
1OC
24P
29B
31~
33P
36B
3O-
3SF
4.4
4P2
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52U
52V
52W
52X
53G
5GY
5HH
5LA
5RE
5VS
66C
6J9
702
7PT
8-0
8-1
8-3
8-4
8-5
8UM
930
A01
A03
A8Z
AAESR
AAEVG
AAHHS
AAHQN
AAIPD
AAKAS
AAMNL
AANHP
AANLZ
AAONW
AASGY
AAXRX
AAYCA
AAZKR
ABCQN
ABCUV
ABDBF
ABEML
ABJNI
ABPVW
ABQWH
ABXGK
ACAHQ
ACBWZ
ACCFJ
ACCZN
ACGFS
ACGOF
ACMXC
ACPOU
ACPRK
ACRPL
ACSCC
ACUHS
ACXBN
ACXQS
ACYXJ
ADBBV
ADBTR
ADEOM
ADIZJ
ADKYN
ADMGS
ADNMO
ADOZA
ADXAS
ADZCM
ADZMN
ADZOD
AEEZP
AEGXH
AEIGN
AEIMD
AENEX
AEQDE
AEUQT
AEUYR
AFBPY
AFEBI
AFFPM
AFGKR
AFPWT
AFRAH
AFWVQ
AFZJQ
AHBTC
AHEFC
AHMBA
AIACR
AITYG
AIURR
AIWBW
AJBDE
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
ALVPJ
AMBMR
AMYDB
AOETA
ASPBG
ATUGU
AVWKF
AZBYB
AZFZN
AZVAB
BAFTC
BDRZF
BFHJK
BHBCM
BMXJE
BROTX
BRXPI
BY8
C45
CAG
COF
CS3
D-6
D-7
D-E
D-F
DCZOG
DPXWK
DR2
DRFUL
DRMAN
DRSTM
DU5
EAD
EAP
EAS
EBB
EBC
EBD
EBS
EBX
EDH
EJD
EMB
EMK
EMOBN
ESX
EX3
F00
F01
F04
F5P
FEDTE
FUBAC
FZ0
G-S
G.N
GODZA
H.X
HF~
HGLYW
HVGLF
HZI
HZ~
IHE
IX1
J0M
K48
KBYEO
LATKE
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LW6
LYRES
MEWTI
MK4
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
N04
N05
N9A
NF~
O66
O9-
OIG
OVD
P2P
P2W
P2X
P2Z
P4B
P4D
PALCI
PQQKQ
Q.N
Q11
QB0
Q~Q
R.K
RIWAO
RJQFR
ROL
RX1
SAMSI
SUPJJ
SV3
TEORI
TUS
UB1
V8K
V9Y
W8V
W99
WBKPD
WHWMO
WIH
WIJ
WIK
WOHZO
WOW
WQJ
WRC
WUP
WVDHM
WXI
WXSBR
X7M
XG1
YFH
YUY
ZGI
ZXP
ZZTAW
~IA
~WT
AAYXX
AEYWJ
AGHNM
AGQPQ
AGYGG
CITATION
AAMMB
AEFGJ
AGXDD
AIDQK
AIDYY
CGR
CUY
CVF
ECM
EIF
NPM
7T5
H94
K9.
7X8
5PM
ID FETCH-LOGICAL-c4446-463964639aefd883e7370ee59fcf18da41a1c24f3602e39f94e24a17a9ac73b03
IEDL.DBID 24P
ISSN 0954-7894
1365-2222
IngestDate Thu Aug 21 18:29:37 EDT 2025
Sun Aug 24 02:54:57 EDT 2025
Fri Jul 25 21:29:07 EDT 2025
Sun Jul 13 01:33:43 EDT 2025
Tue Jul 01 02:53:34 EDT 2025
Thu Apr 24 22:50:34 EDT 2025
Wed Jan 22 17:14:16 EST 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 12
Keywords eczema
network meta‐analysis
calcineurin inhibitor
systematic review
topical steroid
Janus kinase inhibitor
Language English
License Attribution
2024 The Author(s). Clinical & Experimental Allergy published by John Wiley & Sons Ltd.
This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c4446-463964639aefd883e7370ee59fcf18da41a1c24f3602e39f94e24a17a9ac73b03
Notes https://youtu.be/k7CU‐e4Jdpk
This systematic review and network meta‐analysis was funded by the National Institute for Health and Care Research (NIHR) through a Research for Patient Benefit grant to Dr Robert Boyle (NIHR201993) and a Systematic Review Programme Grant to Cochrane Skin at the Centre of Evidence Based Dermatology. The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care.
Funding
.
This article includes Author Insights, a video abstract available at
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-4
content type line 23
ObjectType-Undefined-3
Funding: This systematic review and network meta‐analysis was funded by the National Institute for Health and Care Research (NIHR) through a Research for Patient Benefit grant to Dr Robert Boyle (NIHR201993) and a Systematic Review Programme Grant to Cochrane Skin at the Centre of Evidence Based Dermatology. The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care.
This article includes Author Insights, a video abstract available at: https://youtu.be/k7CU‐e4Jdpk.
ORCID 0000-0002-4913-7580
0000-0001-8269-4496
0000-0002-6113-1173
0000-0002-7000-9364
OpenAccessLink https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fcea.14556
PMID 39219446
PQID 3142420964
PQPubID 36521
PageCount 13
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_11629051
proquest_miscellaneous_3099857445
proquest_journals_3142420964
pubmed_primary_39219446
crossref_primary_10_1111_cea_14556
crossref_citationtrail_10_1111_cea_14556
wiley_primary_10_1111_cea_14556_CEA14556
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate December 2024
PublicationDateYYYYMMDD 2024-12-01
PublicationDate_xml – month: 12
  year: 2024
  text: December 2024
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
– name: Oxford
– name: Hoboken
PublicationTitle Clinical and experimental allergy
PublicationTitleAlternate Clin Exp Allergy
PublicationYear 2024
Publisher Wiley Subscription Services, Inc
John Wiley and Sons Inc
Publisher_xml – name: Wiley Subscription Services, Inc
– name: John Wiley and Sons Inc
References 2023; 53
2015; 162
2015; 15
2005; 152
1997; 195
2013; 42
2020; 183
2020; 17
2019; 366
2020; 36
2024; 54
2017; 176
2023; 3
2013; 8
2021; 51
2014; 134
2022; 2022
2004; 113
2022; 3
2023; 152
1994; 19
2021
2015; 135
2004; 15
2024; 2024
2022; 52
2021; 372
2021; 375
2016; 136
2022; 11
2021; 85
2001; 10
e_1_2_10_23_1
e_1_2_10_24_1
e_1_2_10_21_1
e_1_2_10_22_1
Kelleher M. M. (e_1_2_10_38_1) 2022; 11
e_1_2_10_2_1
Lax S. J. (e_1_2_10_12_1) 2022; 3
e_1_2_10_4_1
e_1_2_10_18_1
e_1_2_10_3_1
e_1_2_10_19_1
e_1_2_10_6_1
e_1_2_10_16_1
e_1_2_10_5_1
e_1_2_10_17_1
e_1_2_10_8_1
e_1_2_10_14_1
e_1_2_10_37_1
e_1_2_10_7_1
e_1_2_10_15_1
e_1_2_10_36_1
e_1_2_10_35_1
e_1_2_10_9_1
e_1_2_10_13_1
e_1_2_10_34_1
e_1_2_10_33_1
e_1_2_10_11_1
e_1_2_10_32_1
e_1_2_10_31_1
e_1_2_10_30_1
Higgins JP (e_1_2_10_20_1) 2021
Steele L. (e_1_2_10_10_1) 2022; 2022
Lax S. J. (e_1_2_10_28_1) 2024; 2024
e_1_2_10_29_1
e_1_2_10_27_1
e_1_2_10_25_1
e_1_2_10_26_1
References_xml – volume: 3
  issue: 3
  year: 2022
  article-title: Strategies for Using Topical Corticosteroids in Children and Adults With Eczema
  publication-title: Cochrane Database of Systematic Reviews
– volume: 17
  issue: 4
  year: 2020
  article-title: CINeMA: An Approach for Assessing Confidence in the Results of a Network Meta‐Analysis
  publication-title: PLoS Medicine
– volume: 15
  start-page: 169
  issue: 3
  year: 2004
  end-page: 178
  article-title: Long‐Term Safety and Tolerability of Pimecrolimus Cream 1% and Topical Corticosteroids in Adults With Moderate to Severe Atopic Dermatitis
  publication-title: Journal of Dermatological Treatment
– volume: 366
  year: 2019
  article-title: RoB 2: A Revised Tool for Assessing Risk of Bias in Randomised Trials
  publication-title: BMJ
– volume: 54
  start-page: 669
  issue: 9
  year: 2024
  end-page: 681
  article-title: Management of Infant Atopic Eczema to Prevent Severe Eczema and Food Allergy
  publication-title: Clinical and Experimental Allergy
– volume: 36
  start-page: 367
  issue: 3
  year: 2020
  end-page: 376
  article-title: Evaluating Patient‐Perceived Control of Atopic Dermatitis: Design, Validation, and Scoring of the Atopic Dermatitis Control Tool (ADCT)
  publication-title: Current Medical Research and Opinion
– volume: 195
  start-page: 10
  issue: 1
  year: 1997
  end-page: 19
  article-title: Clinical Validation and Guidelines for the SCORAD Index: Consensus Report of the European Task Force on Atopic Dermatitis
  publication-title: Dermatology
– volume: 372
  year: 2021
  article-title: The PRISMA 2020 Statement: An Updated Guideline for Reporting Systematic Reviews
  publication-title: BMJ
– volume: 53
  start-page: 495
  year: 2023
  end-page: 510
  article-title: Non‐biologic Systemic Treatments for Atopic Dermatitis: Current State of the Art and Future Directions
  publication-title: Clinical and Experimental Allergy
– volume: 136
  start-page: 1944
  issue: 10
  year: 2016
  end-page: 1949
  article-title: How Clinically Relevant Are Treatment Comparisons of Topical Calcineurin Inhibitor Trials for Atopic Eczema?
  publication-title: Journal of Investigative Dermatology
– year: 2021
– volume: 2022
  issue: 7
  year: 2022
  article-title: Topical Anti‐Inflammatory Treatments for Eczema: Network Meta‐Analysis
  publication-title: Cochrane Database of Systematic Reviews
– volume: 162
  start-page: 777
  issue: 11
  year: 2015
  end-page: 784
  article-title: The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta‐Analyses of Health Care Interventions: Checklist and Explanations
  publication-title: Annals of Internal Medicine
– volume: 85
  start-page: 1065
  issue: 4
  year: 2021
  end-page: 1066
  article-title: New Topical Treatments for Atopic Dermatitis: Active Comparators Are Needed
  publication-title: Journal of the American Academy of Dermatology
– volume: 183
  start-page: 524
  issue: 3
  year: 2020
  end-page: 536
  article-title: Development and Initial Testing of a New Instrument to Measure the Experience of Eczema Control in Adults and Children: Recap of Atopic Eczema (RECAP)
  publication-title: British Journal of Dermatology
– volume: 135
  start-page: 597
  issue: 4
  year: 2015
  end-page: 606
  article-title: Safety and Efficacy of Pimecrolimus in Atopic Dermatitis: A 5‐Year Randomized Trial
  publication-title: Pediatrics
– volume: 152
  start-page: 1493
  issue: 6
  year: 2023
  end-page: 1519
  article-title: Topical Treatments for Atopic Dermatitis (Eczema): Systematic Review and Network Meta‐Analysis of Randomized Trials
  publication-title: Journal of Allergy and Clinical Immunology
– volume: 19
  start-page: 210
  issue: 3
  year: 1994
  end-page: 216
  article-title: Dermatology Life Quality Index (DLQI)—a Simple Practical Measure for Routine Clinical Use
  publication-title: Clinical and Experimental Dermatology
– volume: 152
  start-page: 126
  issue: 1
  year: 2023
  end-page: 135
  article-title: Enhanced Early Skin Treatment for Atopic Dermatitis in Infants Reduces Food Allergy
  publication-title: Journal of Allergy and Clinical Immunology
– volume: 15
  start-page: 951
  year: 2015
  end-page: 985
  article-title: Network Meta‐Analysis
  publication-title: Stata Journal
– volume: 53
  start-page: 4
  issue: 1
  year: 2023
  end-page: 6
  article-title: What Does Clinical and Experimental Allergy Mean by ‘Trusted Evidence in Allergy’?
  publication-title: Clinical and Experimental Allergy
– volume: 53
  start-page: 337
  issue: 3
  year: 2023
  end-page: 352
  article-title: Trends in Eczema Prevalence in Children and Adolescents: A Global Asthma Network Phase I Study
  publication-title: Clinical and Experimental Allergy
– volume: 2024
  year: 2024
  article-title: Topical Anti‐Inflammatory Treatments for Eczema: Network Meta‐Analysis
  publication-title: Cochrane Database of Systematic Reviews
– volume: 375
  year: 2021
  article-title: Conduct and Reporting of Formula Milk Trials: Systematic Review
  publication-title: BMJ
– volume: 51
  start-page: 471
  issue: 3
  year: 2021
  end-page: 482
  article-title: The Epidemiology of Eczema in Children and Adults in England: A Population‐Based Study Using Primary Care Data
  publication-title: Clinical and Experimental Allergy
– volume: 11
  issue: 11
  year: 2022
  article-title: Skin Care Interventions in Infants for Preventing Eczema and Food Allergy
  publication-title: Cochrane Database of Systematic Reviews
– volume: 53
  start-page: 156
  year: 2023
  end-page: 172
  article-title: The Evolving Landscape of Biologic Therapies for Atopic Dermatitis: Present and Future Perspective
  publication-title: Clinical and Experimental Allergy
– volume: 10
  start-page: 11
  issue: 1
  year: 2001
  end-page: 18
  article-title: The Eczema Area and Severity Index (EASI): Assessment of Reliability in Atopic Dermatitis. EASI Evaluator Group
  publication-title: Experimental Dermatology
– volume: 3
  issue: 5
  year: 2023
  article-title: The Long‐Term Safety of Topical Corticosteroids in Atopic Dermatitis: A Systematic Review
  publication-title: Skin Health & Disease
– volume: 134
  start-page: 1527
  issue: 6
  year: 2014
  end-page: 1534
  article-title: The Global Burden of Skin Disease in 2010: An Analysis of the Prevalence and Impact of Skin Conditions
  publication-title: Journal of Investigative Dermatology
– volume: 152
  start-page: 1282
  issue: 6
  year: 2005
  end-page: 1289
  article-title: A Multicentre, Randomized, Double‐Blind, Controlled Study of Long‐Term Treatment With 0.1% Tacrolimus Ointment in Adults With Moderate to Severe Atopic Dermatitis
  publication-title: British Journal of Dermatology
– volume: 8
  issue: 10
  year: 2013
  article-title: Graphical Tools for Network Meta‐Analysis in STATA
  publication-title: PLoS One
– volume: 176
  start-page: 979
  issue: 4
  year: 2017
  end-page: 984
  article-title: Patient‐Oriented Eczema Measure (POEM), a Core Instrument to Measure Symptoms in Clinical Trials: A Harmonising Outcome Measures for Eczema (HOME) Statement
  publication-title: British Journal of Dermatology
– volume: 52
  start-page: 628
  issue: 5
  year: 2022
  end-page: 645
  article-title: Individual Participant Data Meta‐Analysis Versus Aggregate Data Meta‐Analysis: A Case Study in Eczema and Food Allergy Prevention
  publication-title: Clinical and Experimental Allergy
– volume: 42
  start-page: 332
  issue: 1
  year: 2013
  end-page: 345
  article-title: Evaluation of Inconsistency in Networks of Interventions
  publication-title: International Journal of Epidemiology
– volume: 113
  start-page: 832
  issue: 5
  year: 2004
  end-page: 836
  article-title: Revised Nomenclature for Allergy for Global Use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003
  publication-title: Journal of Allergy and Clinical Immunology
– volume: 134
  start-page: 800
  issue: 4
  year: 2014
  end-page: 807
  article-title: The Harmonising Outcome Measures for Eczema (HOME) Statement to Assess Clinical Signs of Atopic Eczema in Trials
  publication-title: Journal of Allergy and Clinical Immunology
– ident: e_1_2_10_26_1
  doi: 10.1136/bmj.n71
– ident: e_1_2_10_25_1
  doi: 10.1371/journal.pmed.1003082
– ident: e_1_2_10_32_1
  doi: 10.1002/ski2.268
– ident: e_1_2_10_33_1
  doi: 10.1111/cea.14515
– ident: e_1_2_10_14_1
  doi: 10.1111/bjd.15179
– ident: e_1_2_10_18_1
  doi: 10.1111/bjd.18780
– volume-title: Cochrane Handbook for Systematic Reviews of Interventions
  year: 2021
  ident: e_1_2_10_20_1
– volume: 11
  issue: 11
  year: 2022
  ident: e_1_2_10_38_1
  article-title: Skin Care Interventions in Infants for Preventing Eczema and Food Allergy
  publication-title: Cochrane Database of Systematic Reviews
– ident: e_1_2_10_27_1
  doi: 10.7326/M14-2385
– ident: e_1_2_10_22_1
  doi: 10.1371/journal.pone.0076654
– volume: 2022
  issue: 7
  year: 2022
  ident: e_1_2_10_10_1
  article-title: Topical Anti‐Inflammatory Treatments for Eczema: Network Meta‐Analysis
  publication-title: Cochrane Database of Systematic Reviews
– ident: e_1_2_10_4_1
  doi: 10.1038/jid.2013.446
– ident: e_1_2_10_8_1
  doi: 10.1016/j.jaad.2021.06.002
– ident: e_1_2_10_2_1
  doi: 10.1111/cea.13784
– ident: e_1_2_10_24_1
  doi: 10.1136/bmj.l4898
– ident: e_1_2_10_16_1
  doi: 10.1159/000245677
– ident: e_1_2_10_7_1
  doi: 10.1016/j.jid.2016.05.104
– ident: e_1_2_10_11_1
  doi: 10.1016/j.jaci.2003.12.591
– ident: e_1_2_10_37_1
  doi: 10.1111/cea.14085
– ident: e_1_2_10_3_1
  doi: 10.1111/cea.14276
– volume: 3
  issue: 3
  year: 2022
  ident: e_1_2_10_12_1
  article-title: Strategies for Using Topical Corticosteroids in Children and Adults With Eczema
  publication-title: Cochrane Database of Systematic Reviews
– ident: e_1_2_10_30_1
  doi: 10.1080/09546630410033781
– volume: 2024
  year: 2024
  ident: e_1_2_10_28_1
  article-title: Topical Anti‐Inflammatory Treatments for Eczema: Network Meta‐Analysis
  publication-title: Cochrane Database of Systematic Reviews
– ident: e_1_2_10_21_1
  doi: 10.1177/1536867X1501500403
– ident: e_1_2_10_9_1
  doi: 10.1016/j.jaci.2023.08.030
– ident: e_1_2_10_6_1
  doi: 10.1111/cea.14263
– ident: e_1_2_10_36_1
  doi: 10.1111/cea.14274
– ident: e_1_2_10_23_1
  doi: 10.1093/ije/dys222
– ident: e_1_2_10_31_1
  doi: 10.1542/peds.2014-1990
– ident: e_1_2_10_5_1
  doi: 10.1111/cea.14301
– ident: e_1_2_10_17_1
  doi: 10.1111/j.1365-2230.1994.tb01167.x
– ident: e_1_2_10_19_1
  doi: 10.1080/03007995.2019.1699516
– ident: e_1_2_10_13_1
  doi: 10.1016/j.jaci.2014.07.043
– ident: e_1_2_10_15_1
  doi: 10.1034/j.1600-0625.2001.100102.x
– ident: e_1_2_10_34_1
  doi: 10.1016/j.jaci.2023.03.008
– ident: e_1_2_10_35_1
  doi: 10.1136/bmj.n2202
– ident: e_1_2_10_29_1
  doi: 10.1111/j.1365-2133.2005.06592.x
SSID ssj0003598
Score 2.484686
SecondaryResourceType review_article
Snippet ABSTRACT Objective Eczema is the most burdensome skin condition worldwide and topical anti‐inflammatory treatments are commonly used to control symptoms. The...
Eczema is the most burdensome skin condition worldwide and topical anti-inflammatory treatments are commonly used to control symptoms. The relative...
ObjectiveEczema is the most burdensome skin condition worldwide and topical anti‐inflammatory treatments are commonly used to control symptoms. The relative...
Trials of topical anti‐inflammatory eczema treatments are mostly industry‐funded, evaluate short‐term outcomes and carry a high risk of bias due to selective...
SourceID pubmedcentral
proquest
pubmed
crossref
wiley
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 960
SubjectTerms Administration, Topical
Anti-Inflammatory Agents - administration & dosage
Anti-Inflammatory Agents - adverse effects
Antibiotics
calcineurin inhibitor
Clinical trials
Contact dermatitis
Eczema
Eczema - drug therapy
Humans
Inflammation
Inhibitor drugs
Janus kinase
Janus kinase inhibitor
Meta-analysis
network meta‐analysis
Phototherapy
Randomized Controlled Trials as Topic
Skin diseases
Steroid hormones
Steroids
Systematic Review
Tacrolimus
Thinning
topical steroid
Treatment Outcome
Title Topical Anti‐Inflammatory Treatments for Eczema: A Cochrane Systematic Review and Network Meta‐Analysis
URI https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fcea.14556
https://www.ncbi.nlm.nih.gov/pubmed/39219446
https://www.proquest.com/docview/3142420964
https://www.proquest.com/docview/3099857445
https://pubmed.ncbi.nlm.nih.gov/PMC11629051
Volume 54
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3NbtQwEB6VVqBeEC1_gVKZigOXoMQexwmcVstWBWkrVLZSb5HtOGoFzVbd7QFOPALP2CfpOE6irgpSL1YkT_5mPPY39vgzwDupfb-oeWyNdjFWiYmN1eRXuZOVrBJlrJ8amB5mB8f49USerMGnfi9M4IcYJty8Z7T9tXdwbRa3nNw6_cGzbGcPYMNvrfXHF3D8NnTDnpouEO1hrPICO1ohn8Yz3Lo6GN1BmHcTJW8D2HYE2n8CjzvoyEbB1luw5ppteBgOk_y1DY-m3TL5U_gxm1945bNRszy7_vP3S1OT4c_bBXU261PLF4wAK5vY3-5cf2QjNp7bUxq5HPs-sDuzsHTAdFOxw5AwzqZuqemZPZvJMzjen8zGB3F3qkJskWK_GAmTZL7Qrq7yXDglVOKcLGpbp3mlMdWp5ViLLOFOFHWBjqNOlS60VcIk4jmsN_PGvQRmkLukUFahEVhJS7GWQEcBlhJapjqP4H2v3tJ2lOP-5IufZR96kCXK1hIR7A2iF4Fn419CO72Nys7VFqXwe_U4RWIYwduhmpzEr3yQ0uZXJEM4OJcKUUbwIph0eAsBxLQgxUSQrxh7EPAE3Ks1zdlpS8Sdphn3_Gb0n227-P-Xl-PJqL14dX_R17DJCUGF3JkdWF9eXrk3hICWZrdt6VR-PuI3GFIEFg
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1LT9wwEB5RUB8XVOgrlLZu1UMvqRJ7HCcVl9Vq0VLYVaUuErfIcRyBgCwqy6E99SfwG_kljOMkYkWReokiZfKa8djfeMafAT5L7fpFzUNTaBtiGRVhYTT5VWplKctIFcZNDUymyfgQvx_JoxXY6dbCeH6IfsLNeUbTXzsHdxPSd7zcWP3V0Wwnj2ANCZe7Ns3xR98PO246z7SHoUozbHmFXB1Pf-vyaHQPYt6vlLyLYJshaPc5rLfYkQ28sTdgxdab8NjvJvl7E55M2jz5CzidzS-c9tmgXpzc_L3eqyuy_HmTUWezrrb8khFiZSPzx57rb2zAhnNzTEOXZT97emfmcwdM1yWb-opxNrELTc_s6ExewuHuaDYch-22CqFBCv5CJFCSuIO2VZmmwiqhImtlVpkqTkuNsY4Nx0okEbciqzK0HHWsdKaNEkUkXsFqPa_tG2AFchtlyigsBJbSULAl0FKEpYSWsU4D-NKpNzct57jb-uIs72IPskTeWCKAT73ohSfa-JfQdmejvPW1y1y4xXqcQjEM4GN_mbzEpT5IafMrkiEgnEqFKAN47U3av4UQYpyRYgJIl4zdCzgG7uUr9clxw8Qdxwl3BGf0n027ePjL8-Fo0Jxs_b_oB3g6nk0O8oO96f5beMYJTvlCmm1YXfy6su8IDi2K902rvwUVtQai
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3NbtQwEB6VIiouFRQogQIGceASlNjjOGlPq2VXLbCrSmyl3iLHcdQKml3R7aE99RF4xj5Jx3ESdVWQuESRMvmb8djfeMafAT5K7fpFzUNTaBtiGRVhYTT5VWplKctIFcZNDUymyf4Rfj2Wx2uw162F8fwQ_YSb84ymv3YOviirO05urP7sWLaTB_DQJftcPR_Hw74bdtR0nmgPQ5Vm2NIKuTKe_tbVwegewrxfKHkXwDYj0PgJbLbQkQ28rZ_Cmq234JHfTPJyCzYmbZr8GfyczRdO-WxQL09vrv8c1BUZ_qxJqLNZV1p-zgiwspG5smd6lw3YcG5OaOSy7EfP7sx86oDpumRTXzDOJnap6Zkdm8lzOBqPZsP9sN1VITRIsV-IhEkSd9C2KtNUWCVUZK3MKlPFaakx1rHhWIkk4lZkVYaWo46VzrRRoojEC1iv57V9CaxAbqNMGYWFwFIairUEWgqwlNAy1mkAnzr15qalHHc7X_zKu9CDLJE3lgjgQy-68DwbfxPa6WyUt652ngu3Vo9TJIYBvO8vk5O4zAcpbX5BMoSDU6kQZQDb3qT9WwggxhkpJoB0xdi9gCPgXr1Sn540RNxxnHDHb0b_2bSLf395PhwNmpNX_y_6DjYOv4zz7wfTb6_hMScw5ctodmB9-fvCviEwtCzeNo3-FnB6Bcs
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Topical+Anti%E2%80%90Inflammatory+Treatments+for+Eczema%3A+A+Cochrane+Systematic+Review+and+Network+Meta%E2%80%90Analysis&rft.jtitle=Clinical+and+experimental+allergy&rft.au=Lax%2C+Stephanie+J.&rft.au=Van+Vogt%2C+Eleanor&rft.au=Candy%2C+Bridget&rft.au=Steele%2C+Lloyd&rft.date=2024-12-01&rft.pub=John+Wiley+and+Sons+Inc&rft.issn=0954-7894&rft.eissn=1365-2222&rft.volume=54&rft.issue=12&rft.spage=960&rft.epage=972&rft_id=info:doi/10.1111%2Fcea.14556&rft_id=info%3Apmid%2F39219446&rft.externalDocID=PMC11629051
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0954-7894&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0954-7894&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0954-7894&client=summon